GLSI Stock Rises After FDA Approves Commercial GP2 for Phase III Trial

Global Life Sciences Inc. (GLSI) shares surged 18.7% to $45.60 on January 22, 2026, following the U.S. Food and Drug Administration’s clearance to use its commercial-grade GP2 in an ongoing Phase III clinical trial for a neurodegenerative disorder. The approval accelerates the company's development timeline and reduces regulatory uncertainty for the candidate therapy. The FDA’s decision allows GLSI to proceed with patient dosing using commercially manufactured GP2, eliminating the need for investigational batch production. This milestone comes after successful Phase II results showing a 32% improvement in cognitive function markers. GLSI reported $21 million in Q4 revenue, up 19% year-over-year, driven by increased demand for its diagnostic platforms. The stock traded as high as $46.15 during intraday trading, marking its best single-day gain since June 2025. Analysts at Morgan Stanley raised their target price to $52 from $40, citing improved path to commercialization.